Really liked in the presentation yesterday how they emphasized there is no competition in the ARDS space currently. Think that's important... Even if the efficacy seems something like 50% - 60% (as opposed to the 83% on the initial 12 patients, although im tipping efficacy in line with agvhd C/D @ approx 75% - 80%), certainly would be a very useful product to help tackle the pandemic, particularly with the demonstrated safety profile of the product, even around 40 - 50% could suffice for FDA approval given minimal/no other alternatives in sight.
MSB Trading - 2020, page-11290
-
- There are more pages in this discussion • 11,871 more messages in this thread...
This thread is closed.
You may not reply to this discussion at this time.
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.22 |
Change
-0.088(6.70%) |
Mkt cap ! $1.364B | |||
| Open | High | Low | Value | Volume |
| $1.27 | $1.30 | $1.17 | $10.37M | 8.406M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 9 | 15704 | $1.22 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.22 | 35200 | 12 |
View Market Depth
| Last trade - 11.13am 24/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |